[1]
“A new paradigm of cardiohematological monitoring in patients with chronic myeloid leukemia taking tyrosine kinase inhibitors”, UJC, vol. 29, no. 1-2, pp. 72–86, Jul. 2022, doi: 10.31928/1608-635X-2022.1-2.7286.